NASD · Healthcare · Drug Manufacturers - Specialty & Generic · USA
Sonoma Pharmaceuticals Inc is a micro cap company (market value under $300 million) in the Drug Manufacturers - Specialty & Generic industry.
Sonoma Pharmaceuticals develops and produces stabilized hypochlorous acid products for wound care, eye care, dermatology, podiatry, animal health, and non-toxic disinfectants. The company sells its medical devices through direct sales and distribution partners across multiple countries worldwide. Its product portfolio addresses various healthcare applications including acute and chronic wound treatment and skin conditions.
From its FY2026 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Sonoma Pharmaceuticals Inc stock.
No reliable verdict: intrinsic value $4.93 per share, market price $0.83 (as of 2026-11-17).
A revenue multiple, discounted for its losses, would put the shares at $4.93: 6 times the price of $0.83. A multiple has nothing to stand on when a company earns almost nothing on its sales and has no filings in our archive, so we do not publish a verdict on this one.
All 82 Drug Manufacturers - Specialty & Generic stocks
We do not publish a verdict on SNOA. A revenue multiple, discounted for its losses, would put the shares at $4.93: 6 times the price of $0.83. A multiple has nothing to stand on when a company earns almost nothing on its sales and has no filings in our archive, so we do not publish a verdict on this one.
We do not publish one (as of the 2026-11-17 close). A revenue multiple, discounted for its losses, would put the shares at $4.93: 6 times the price of $0.83. A multiple has nothing to stand on when a company earns almost nothing on its sales and has no filings in our archive, so we do not publish a verdict on this one.